A detailed history of Royal Bank Of Canada transactions in Geron Corp stock. As of the latest transaction made, Royal Bank Of Canada holds 64,243 shares of GERN stock, worth $256,329. This represents 0.0% of its overall portfolio holdings.

Number of Shares
64,243
Previous 118,637 45.85%
Holding current value
$256,329
Previous $503,000 42.15%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$4.17 - $4.99 $226,822 - $271,426
-54,394 Reduced 45.85%
64,243 $291,000
Q2 2024

Aug 14, 2024

BUY
$3.1 - $5.09 $280,007 - $459,754
90,325 Added 319.03%
118,637 $503,000
Q1 2024

Nov 05, 2024

SELL
$1.75 - $3.44 $158,068 - $310,718
-90,325 Reduced 76.14%
28,312 $93,000
Q1 2024

May 15, 2024

SELL
$1.75 - $3.44 $211,935 - $416,604
-121,106 Reduced 81.05%
28,312 $93,000
Q4 2023

Feb 14, 2024

BUY
$1.74 - $2.31 $141,418 - $187,745
81,275 Added 119.27%
149,418 $315,000
Q3 2023

Nov 14, 2023

BUY
$2.11 - $3.28 $61,837 - $96,126
29,307 Added 75.46%
68,143 $144,000
Q2 2023

Aug 14, 2023

BUY
$1.97 - $3.69 $18,370 - $34,409
9,325 Added 31.6%
38,836 $124,000
Q1 2023

May 15, 2023

SELL
$2.14 - $3.4 $67,947 - $107,953
-31,751 Reduced 51.83%
29,511 $64,000
Q4 2022

Feb 14, 2023

BUY
$2.03 - $2.42 $114,169 - $136,103
56,241 Added 1120.12%
61,262 $148,000
Q3 2022

Nov 14, 2022

BUY
$1.67 - $2.94 $4,002 - $7,047
2,397 Added 91.35%
5,021 $11,000
Q2 2022

Aug 15, 2022

SELL
$1.19 - $1.65 $19,874 - $27,556
-16,701 Reduced 86.42%
2,624 $4,000
Q1 2022

May 16, 2022

SELL
$0.99 - $1.6 $38,563 - $62,324
-38,953 Reduced 66.84%
19,325 $26,000
Q4 2021

Feb 14, 2022

BUY
$1.22 - $1.72 $35,630 - $50,232
29,205 Added 100.45%
58,278 $71,000
Q3 2021

Nov 15, 2021

BUY
$1.2 - $1.5 $9,396 - $11,745
7,830 Added 36.86%
29,073 $40,000
Q2 2021

Aug 16, 2021

BUY
$1.25 - $1.83 $26,553 - $38,874
21,243 New
21,243 $30,000

Others Institutions Holding GERN

About GERON CORP


  • Ticker GERN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 377,819,008
  • Market Cap $1.51B
  • Description
  • Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...
More about GERN
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.